Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 301 to 310 of 797

TitleReference numberPublishedLast updated
Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangementTA722
Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndromeTA139
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphomaTA720
Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancerTA721
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiencyTA716
Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal)TA717
Ixekizumab for treating axial spondyloarthritisTA718
Secukinumab for treating non-radiographic axial spondyloarthritisTA719
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)TA714
Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failedTA715

Results per page

  1. 10
  2. 25
  3. 50
  4. All